Leuprolide acetate 11.25 mg ( DrugBank: Leuprolide, Acetate )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
76下垂体性ゴナドトロピン分泌亢進症3

76. 下垂体性ゴナドトロピン分泌亢進症


臨床試験数 : 29 薬物数 : 44 - (DrugBank : 14) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00667446
(ClinicalTrials.gov)
December 200824/4/2008Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious PubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious PubertyPrecocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious PubertyDrug: Leuprolide Acetate 3 Month DepotAbbVie (prior sponsor, Abbott)NULLCompletedN/AN/AAll72Phase 3United States;Puerto Rico
2NCT00635817
(ClinicalTrials.gov)
June 20087/3/2008A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious PubertyA Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious PubertyPuberty, PrecociousDrug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mgAbbottNULLCompleted2 Years11 YearsAll84Phase 3United States;Puerto Rico
3EUCTR2014-004494-16-Outside-EU/EEA
(EUCTR)
03/12/2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product’
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
72United States;Puerto Rico